0.8853
price down icon4.84%   -0.045
after-market アフターアワーズ: .89 0.0047 +0.53%
loading
前日終値:
$0.9303
開ける:
$0.91
24時間の取引高:
338.17K
Relative Volume:
0.37
時価総額:
$117.12M
収益:
$3.25M
当期純損益:
$-116.80M
株価収益率:
-0.2903
EPS:
-3.05
ネットキャッシュフロー:
$-98.17M
1週間 パフォーマンス:
-28.02%
1か月 パフォーマンス:
-2.28%
6か月 パフォーマンス:
-29.74%
1年 パフォーマンス:
-78.14%
1日の値動き範囲:
Value
$0.8603
$0.91
1週間の範囲:
Value
$0.8603
$1.27
52週間の値動き範囲:
Value
$0.7082
$4.60

Rapt Therapeutics Inc Stock (RAPT) Company Profile

Name
名前
Rapt Therapeutics Inc
Name
セクター
Healthcare (1170)
Name
電話
(650) 489-9000
Name
住所
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Name
職員
67
Name
Twitter
Name
次回の収益日
2024-11-11
Name
最新のSEC提出書
Name
RAPT's Discussions on Twitter

RAPT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RAPT
Rapt Therapeutics Inc
0.8853 162.72M 3.25M -116.80M -98.17M -3.05
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-22 再開されました H.C. Wainwright Buy
2024-12-26 アップグレード H.C. Wainwright Neutral → Buy
2024-11-13 ダウングレード Stifel Buy → Hold
2024-11-11 ダウングレード JP Morgan Neutral → Underweight
2024-11-11 ダウングレード Piper Sandler Overweight → Neutral
2024-05-14 ダウングレード Wolfe Research Outperform → Peer Perform
2024-05-10 ダウングレード Barclays Overweight → Equal Weight
2024-05-10 ダウングレード Guggenheim Buy → Neutral
2024-02-22 ダウングレード UBS Buy → Neutral
2024-02-21 ダウングレード H.C. Wainwright Buy → Neutral
2024-02-21 ダウングレード JP Morgan Overweight → Neutral
2024-02-21 ダウングレード Leerink Partners Outperform → Market Perform
2024-02-20 ダウングレード Cantor Fitzgerald Overweight → Neutral
2024-02-16 開始されました Evercore ISI Outperform
2024-02-15 開始されました Wolfe Research Outperform
2023-09-14 開始されました Berenberg Buy
2023-08-09 開始されました Stifel Buy
2023-06-15 開始されました Barclays Overweight
2023-01-04 開始されました Guggenheim Buy
2022-12-01 開始されました Goldman Buy
2022-09-21 開始されました CapitalOne Overweight
2022-05-24 再開されました Cantor Fitzgerald Overweight
2021-12-09 開始されました JP Morgan Overweight
2021-08-12 開始されました SVB Leerink Outperform
2021-06-21 開始されました Piper Sandler Overweight
2020-06-01 開始されました H.C. Wainwright Buy
2020-05-19 開始されました Cantor Fitzgerald Overweight
2020-04-13 開始されました ROTH Capital Buy
2019-11-25 開始されました BMO Capital Markets Outperform
2019-11-25 開始されました UBS Buy
2019-11-25 開始されました Wells Fargo Outperform
すべてを表示

Rapt Therapeutics Inc (RAPT) 最新ニュース

pulisher
May 28, 2025

RAPT Therapeutics Faces Nasdaq Delisting Notice - TipRanks

May 28, 2025
pulisher
May 26, 2025

What is HC Wainwright’s Forecast for RAPT Q2 Earnings? - Defense World

May 26, 2025
pulisher
May 25, 2025

UBS Group Cuts RAPT Therapeutics (NASDAQ:RAPT) Price Target to $1.00 - Defense World

May 25, 2025
pulisher
May 24, 2025

RAPT Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by HC Wainwright - Defense World

May 24, 2025
pulisher
May 23, 2025

D. E. Shaw & Co. Inc. Sells 278,173 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 23, 2025
pulisher
May 22, 2025

RAPT Stock: HC Wainwright & Co. Announces New Price Target | RAP - GuruFocus

May 22, 2025
pulisher
May 22, 2025

UBS Adjusts Price Target for Rapt Therapeutics (RAPT) | RAPT Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

RAPT Analyst Update: UBS Adjusts Price Target to $1 | RAPT Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Rapt Therapeutics (RAPT) Receives Buy Rating with Promising Outl - GuruFocus

May 22, 2025
pulisher
May 22, 2025

UBS Adjusts Price Target for Rapt Therapeutics (RAPT) | RAPT Sto - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Rapt Therapeutics (RAPT) Receives Buy Rating with Promising Outlook | RAPT Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

UBS cuts Rapt Therapeutics stock target to $1 from $2 By Investing.com - Investing.com UK

May 22, 2025
pulisher
May 19, 2025

Comerica Bank Purchases Shares of 58,040 RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 19, 2025
pulisher
May 18, 2025

Dimensional Fund Advisors LP Sells 105,231 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 18, 2025
pulisher
May 16, 2025

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

May 16, 2025
pulisher
May 09, 2025

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Hold” by Analysts - Defense World

May 09, 2025
pulisher
May 09, 2025

RAPT Therapeutics Reports Improved Q1 2025 Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

RAPT Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView

May 08, 2025
pulisher
May 05, 2025

RAPT Therapeutics Reports Third Quarter 2024 Financial Results - ADVFN

May 05, 2025
pulisher
May 05, 2025

RAPT Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 04, 2025

Renaissance Technologies LLC Has $584,000 Stock Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 04, 2025
pulisher
May 03, 2025

JPMorgan Chase & Co. Raises Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 03, 2025
pulisher
May 02, 2025

There is no way RAPT Therapeutics Inc (RAPT) can keep these numbers up - Sete News

May 02, 2025
pulisher
May 01, 2025

A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Market Recap: RAPT Therapeutics Inc (RAPT)’s Positive Momentum, Closing at 0.93 - DWinneX

May 01, 2025
pulisher
May 01, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Acquired by Geode Capital Management LLC - Defense World

May 01, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 24, 2025

RAPT Therapeutics Inc (RAPT) is a good investment, but the stock may be overvalued - uspostnews.com

Apr 24, 2025
pulisher
Apr 21, 2025

Stock Surge: RAPT Therapeutics Inc (RAPT) Closes at 0.79, Marking a -1.32 Increase/Decrease - DWinneX

Apr 21, 2025
pulisher
Apr 18, 2025

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth? - Yahoo Finance

Apr 18, 2025
pulisher
Apr 18, 2025

RAPT stock touches 52-week low at $0.78 amid sharp annual decline - Investing.com Canada

Apr 18, 2025
pulisher
Apr 17, 2025

RAPT stock touches 52-week low at $0.78 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 15, 2025

Rapt Therapeutics appoints Jessica Savage as VP, clinical development - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

RAPT Therapeutics (RAPT) Strengthens Leadership with New VP for Clinical Development | RAPT Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

RAPT Therapeutics Deepens Expertise in Allergic Diseases - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Top Allergy Expert Joins RAPT to Accelerate Novel Food Allergy Treatment Pipeline - Stock Titan

Apr 15, 2025
pulisher
Apr 14, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

40,218 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Bought by Sei Investments Co. - Defense World

Apr 13, 2025
pulisher
Mar 20, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN

Mar 19, 2025
pulisher
Mar 13, 2025

Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

H.C. Wainwright maintains $10 target on RAPT Therapeutics stock By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks

Mar 10, 2025
pulisher
Mar 07, 2025

RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 07, 2025
pulisher
Mar 07, 2025

Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan

Mar 07, 2025
pulisher
Mar 07, 2025

Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks

Mar 06, 2025

Rapt Therapeutics Inc (RAPT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
大文字化:     |  ボリューム (24 時間):